Study consistent with trial results for dabigatran and warfarin in atrial fibrillation

November 13, 2017, Kaiser Permanente

A study of two medications that can reduce risk of ischemic stroke in people with atrial fibrillation showed that outcomes in typical patients with atrial fibrillation align well with those seen in clinical trials. The findings were published on Nov. 14 in Annals of Internal Medicine.

This research, led by Alan Go, MD, director of the Comprehensive Clinical Research Unit within the Kaiser Permanente Division of Research, marks the first major study to examine outcomes of therapies for atrial fibrillation from the U.S. Food and Drug Administration Sentinel Initiative, a national multi-institution network to monitor the safety of new medical products after they reach the market.

Atrial fibrillation is an irregular heart rhythm that increases risk. To reduce this risk, often receive treatment with the blood thinner warfarin, which has been in use since the 1950s, or a newer alternative such as , approved by FDA in late 2010.

The analysis showed that both medications were associated with similar rates of ischemic stroke and overall bleeding. However, people taking dabigatran were less likely to experience bleeding in the brain, which can be dangerous or deadly. These findings were consistent with the results of prior clinical trials that compared the two drugs.

"Our study provides reassurance that stroke-related outcomes seen with dabigatran in selected trial participants translate into usual clinical care for patients with atrial fibrillation," Dr. Go said. "Importantly, while risks of ischemic stroke were similar for dabigatran and warfarin, dabigatran was safer from the standpoint of a lower risk of brain bleeds."

The study also addressed rates associated with each drug, but the results were inconclusive. Patients on dabigatran were more likely to experience a heart attack than patients on warfarin, but the statistical strength and consistency of this finding was unclear.

"The jury is still out," Dr. Go said. "We need more research to rule out the possibility that there might be a higher risk of heart attack with dabigatran in certain patients, such as those who are older and men."

National collaboration

The analysis incorporated data from 50,578 adults aged 21 and older with atrial . Half started dabigatran and half started warfarin between November 2010 and May 2014. To ensure a fair comparison, patients taking dabigatran versus warfarin were statistically matched according to similar demographics, use of additional medications, and many other characteristics.

Patient data was contributed by eight Sentinel collaborators: Kaiser Permanente Northern California, Kaiser Permanente Washington, Aetna, Harvard Pilgrim Health Care Institute, HealthCore, Inc., HealthPartners Institute, Humana Comprehensive Health Insights, Inc., and Optum: Optum Epidemiology.

"The Sentinel program enabled us to look at adults of all ages—not just older patients—who received care across a variety of settings," said senior author Joshua Gagne, PharmD, ScD, of Harvard Medical School. "Ours isn't the first study to address this question outside of , but it is the most wide-ranging and nationally representative."

Future research should examine which types of patients benefit most from which stroke-prevention strategies, Dr. Go said. Indeed, the new study mirrored prior clinical trial results showing higher rates of gastrointestinal bleeding with dabigatran in older patients and those with kidney disease, emphasizing that warfarin is likely still a better choice for some.

Dr. Go's research is now looking at how different patient characteristics might affect ideal treatment choice to optimize outcomes for .

Explore further: When two is better than three: Dual antithrombotic therapy cuts bleeding risk

Related Stories

When two is better than three: Dual antithrombotic therapy cuts bleeding risk

August 28, 2017
Using just two anticlotting medicines for patients who have atrial fibrillation and have had a stent placed in a heart artery is safer than using the current standard treatment of three medications, according to a new study ...

Lower inpatient costs for dabigatran, rivaroxaban in A-fib

January 17, 2017
(HealthDay)—For patients with newly diagnosed atrial fibrillation (AF), inpatient costs are lower with dabigatran and rivaroxaban than with warfarin, according to a letter published online in the Jan. 24 issue of the Journal ...

How safe and effective are new drugs for stroke prevention?

October 3, 2016
For decades, warfarin was the only oral blood thinner available to reduce the risk of stroke for patients with atrial fibrillation. Warfarin use is cumbersome, because it requires ongoing blood test to monitor the effect ...

Risk of hemorrhage with statins and stroke prevention drug combination

November 21, 2016
Two commonly prescribed statins appear to be associated with a higher risk of bleeding than others when combined with dabigatran, a drug often used for preventing strokes in patients with atrial fibrillation, according to ...

Use of novel oral anticoagulants increasing in A-fib

June 15, 2015
(HealthDay)—For patients with atrial fibrillation hospitalized with stroke or transient ischemic attack, use of novel oral anticoagulants (NOACs) has increased over time, according to a study published online June 9 in ...

Lower risk of gastrointestinal bleeding for apixaban

April 10, 2017
(HealthDay)—For patients receiving direct oral anticoagulant (DOAC) agents for non-valvular atrial fibrillation, apixaban is associated with a lower risk of gastrointestinal (GI) bleeding than rivaroxaban or dabigatran, ...

Recommended for you

Resolvin D-1 limits kidney damage after heart attacks

February 20, 2018
A heart attack triggers an acute inflammatory response at the damaged portion of the heart's left ventricle. If this acute inflammation lingers, it can lead to stretching of the ventricle and heart failure. The inflammation ...

Stroke drug demonstrates safety in clinical trial

February 20, 2018
A preliminary Phase 2 clinical trial has demonstrated that patients with acute ischemic stroke, the most common type of stroke, can safely tolerate high doses of 3K3A-APC, a promising anti-stroke drug invented at The Scripps ...

Women once considered low risk for heart disease show evidence of previous heart attack scars

February 20, 2018
Women who complain about chest pain often are reassured by their doctors that there is no reason to worry because their angiograms show that the women don't have blockages in the major heart arteries, a primary cause of heart ...

Can your cardiac device be hacked?

February 20, 2018
Medical devices, including cardiovascular implantable electronic devices could be at risk for hacking. In a paper publishing online today in the Journal of the American College of Cardiology, the American College of Cardiology's ...

A drug long used to treat gout may help adult heart failure patients

February 20, 2018
Researchers at the University of Cincinnati (UC) College of Medicine have shown that probenecid, a drug long used to treat gout, may be able to improve heart function in adult patients who experience heart failure.

Heart attack symptoms often misinterpreted in younger women

February 20, 2018
Young women who report heart attack symptoms are more likely to have them dismissed by their providers as not heart related, a new study led by the Yale School of Public Health (YSPH) finds.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.